6533b7cefe1ef96bd1257b7c
RESEARCH PRODUCT
Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia
Marco CuzzupoliAldo E. TammaroL. BartorelliVicenzo MariglianoMario FioravantiD. CucinottaG. AbateAntonio CapursoUmberto SeninGiuseppe Barbagallo-sangiorgisubject
Agingmedicine.medical_specialtyHealth (social science)Vascular diseaseCerebral infarctionbusiness.industrymedicine.diseasePlaceboClinical trialOral administrationRating scaleAnesthesiamedicinePhysical therapyIdebenoneDementiaGeriatrics and GerontologybusinessGerontologymedicine.drugdescription
Abstract In this randomized double-blind, placebo controlled, multicentre study on 108 elderly patients with mild to moderate mental deterioration of vascular origin, idebenone — a benzoquinone derivative with a hydroxyalkyl side chain — proved to be therapeutically effective in the treatment of multi-infarct dementia. The oral administration of idebenone 45 mg/day b.i.d. for 120 days significantly improved the scores of the following test in comparison with placebo: Mini Mental State, Randt Memory Test, Gottfries Rating Scale, Token Test, Toulouse Pieron Test, indicating improvements in memory attention and cognitivity. The drug was well tolerated and effective in patients with multi-infarct dementria. No changes in laboratory parameters were observed either before or after treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1992-11-01 | Archives of Gerontology and Geriatrics |